Improved survival in patients with first relapsed or refractory acute myeloid leukemia (AML) treated with vosaroxin plus cytarabine versus placebo plus cytarabine: Results of a phase 3 double-blind randomized controlled multinational study (VALOR) Meeting Abstract
| Authors: | Ravandi, F.; Ritchie, E.; Sayar, H.; Lancet, J.; Craig, M. D.; Vey, N.; Strickland, S. A.; Schiller, G.; Jabbour, E.; Erba, H. P.; Pigneux, A.; Horst, H. A.; Recher, C.; Klimek, V. M.; Cortes, J.; Feldman, E. J.; Craig, A. R.; Fox, J. A.; Ward, R.; Smith, J.; Acton, G.; Mehta, C.; Kantarjian, H. M.; Stuart, R. K. |
| Abstract Title: | Improved survival in patients with first relapsed or refractory acute myeloid leukemia (AML) treated with vosaroxin plus cytarabine versus placebo plus cytarabine: Results of a phase 3 double-blind randomized controlled multinational study (VALOR) |
| Meeting Title: | 56th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 124 |
| Issue: | 21 |
| Meeting Dates: | 2014 Dec 6-9 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2014-12-06 |
| Language: | English |
| ACCESSION: | WOS:000349243506038 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V124.21.LBA-6.LBA-6 |
| Notes: | Meeting Abstract: LBA-6 -- 56th Annual Meeting of the American-Society-of-Hematology -- DEC 06-09, 2014 -- San Francisco, CA -- Source: Wos |
